Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant

Prashant Hiwarkar(Birmingham Children's Hospital), Persis Amrolia(Great Ormond Street Hospital), Ponni Sivaprakasam(Bristol Royal Hospital for Children), Su Han Lum(Royal Manchester Children's Hospital), Hemalatha Doss(Great North Children's Hospital), Ciara O’Rafferty(Birmingham Children's Hospital), Toni Petterson(Royal Marsden Hospital), Katharine Patrick(Sheffield Children's Hospital), Juliana Silva(Great Ormond Street Hospital), Mary Slatter(Great North Children's Hospital), Sarah Lawson(Birmingham Children's Hospital), Kanchan Rao(Great Ormond Street Hospital), Colin G. Steward(Bristol Royal Hospital for Children), Adam Gassas(Bristol Royal Hospital for Children), Paul Veys(Great Ormond Street Hospital), Robert Wynn(Royal Manchester Children's Hospital)
Blood
February 3, 2017
Cited by 127Open Access
Full Text

Abstract

< .05). One patient experienced abdominal cramps and diarrhea necessitating interruption of brincidofovir and none developed nephrotoxicity with brincidofovir. Thus, brincidofovir is well-tolerated and highly efficacious in controlling adenoviremia during the lymphopenic phase of HCT.


Related Papers

No related papers found

Powered by citation graph analysis